Based on this data, pembrolizumab in combination with trastuzumab, fluoropyrimidine, and platinum-based chemotherapy received a favourable recommendation from the EMA CHMP for the first-line treatment of HER2-positive GEA in tumours expressing PD-L1, with a CPS ≥ 1. The gene discussed is CD274; the disease is neoplasm.